Good MorningThe S&P 500 stood tall the day before the Independence Day holiday and set a new all-time high. The market broke above a critical resistance point and set itself up to continue higher in the second half. The technical targets suggest the S&P 500 will reach 6,100 by year's end, and a higher high may be reached. The market is being driven by tech and AI, and the second half's outlook includes broadening within the market. As it is, a few key players are reaping the rewards, but more are expected to participate in the boom as AI services expand.
The highlights of the second half of 2024 will include the FOMC. The FOMC is tracking for an interest rate cut by September and possibly two by the end of the year. The risk for bulls is that the Fed is unlikely to cut much or quickly because it risks accelerating inflation. In this light, the S&P 500 can continue to rally in 2024 but may hit a ceiling early next year. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Consumer Staples | |
The Fourth of July is a cornerstone of American tradition that signifies a time for celebration, family gatherings, and festive cookouts. This holiday's cultural impact resonates deeply within the consumer landscape, often driving a surge in spending on goods and services in the consumer discretio... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Healthcare | |
In a holiday-shortened week, shares of AbbVie Inc. (NYSE: ABBV) are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson (NYSE: JNJ), which is down 0.68%, and Pfizer Inc. (NYSE: PFE), which is down 1.38%.
... Read the Full Story |
|
Technology | |
That's right, the better stock to watch for those investors who value momentum over everything else in the technology sector is not actually NVIDIA Co. (NASDAQ: NVDA). Understanding that the artificial intelligence wave is only getting started, especially considering that chip and semiconductor te... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
The market for GitLab (NASDAQ: GTLB) collapsed in late May when it announced high-severity flaws in its platform. The news was especially shocking coming from a DevSecOps platform, but the impact on the share price has been short-lived. The market is already rebounding from its lows and is likel... Read the Full Story |
|
Consumer Discretionary | |
Despite sinking to an all-time low in April, shares of Rivian Automotive, Inc. (NASDAQ: RIVN) have been on a heater in recent weeks. The electric vehicle (EV) maker, considered one of the stronger alternatives to the king of EVs, Tesla Inc (NASDAQ: TSLA), has seen its shares gain more than 80% i... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Industrials | |
Clarivate (NYSE: CLVT) may not be the cheapest AI stock worth buying, but it is inexpensive and set up to rebound strongly over the next few quarters. Trading at a mere 7.5x its earnings outlook for 2025, it is a super-deep value compared to leading AI plays, and the estimates for earnings growth ... Read the Full Story |
|
Markets | |
We recently carried out a survey among 3,000 business executives to identify which cities they consider hidden gems for launching a startup. The results are below.
Key Findings & Implications
Overall:
Regional Clusters: Many hidden gem cities are clustered in regions known for their str... Read the Full Story |
|
Markets | | A significant short interest may result in a squeeze, but what do the prominent short positions represent? Understanding the implications of high short interest, including the potential for significant price volatility and the underlying health of companies, is essential for retail traders.
What is... Read the Full Story |
|
Energy | |
Most of the market attention remains with the technology sector today, where all of 2024 has been centered around every stock related to artificial intelligence, particularly those in the chip and semiconductor space. When reading this, most investors probably thought of NVIDIA Co. (NASDAQ: NVDA) ... Read the Full Story |
|
Industrials | |
Generac Holdings Inc. (NYSE: GNRC) has long been synonymous with backup power generation, holding a commanding presence in a market driven by the need for energy reliability. However, recent developments have created a complex narrative, leaving investors to decipher a mixture of positive and co... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California. | | View Today's Stock Pick |
|
